Compare Kohl's Corporation (KSS) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kohl's Corporation vs Organon & Co. Common Stock — how do they compare? Kohl's Corporation trades at $21.11 (market cap $2.39B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Organon & Co. Common Stock is the larger of the two by market cap, and Kohl's Corporation pays the higher dividend (2.37%). Which is the better fit depends on your goals — on Pluang, investors hold Kohl's Corporation for 48 Days and Organon & Co. Common Stock for 0 Days on average.
| KSS | OGN | |
|---|---|---|
Market Cap | $2.39B | $3.62B |
Volume | 4,591,325 | 2,892,999 |
Sector | Consumer Cyclical | Health |
52-Week High | $24.71 | $13.81 |
52-Week Low | $11.72 | $5.70 |
Typical Hold Time | 48 Days | 0 Days |
Enterprise Value | $7.99B | $11.04B |
Dividend Yield | 2.37% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kohl's (KSS) trades at $21.15, down slightly by 0.09% on the day, with the stock showing bullish technical signals from moving averages. The company has beaten earnings expectations for three consecutive quarters, including a significant Q2 2026 beat of $1.28 EPS versus $0.58 expected. Despite declining revenues, Kohl's maintains attractive valuation metrics with a P/E of 9.06 and P/S of 0.16, while recent management changes and operational improvements provide potential catalysts.
The investment case centers on deep value metrics and operational turnaround potential, though persistent revenue declines and competitive pressures remain key risks. Analyst sentiment is mixed with 30% buy ratings but a consensus price target of $15.50 below current levels, suggesting cautious optimism about the company's ability to stabilize sales and improve profitability in a challenging retail environment.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kohl's Corporation
Kohl's operates 1,165 department stores in 49 states that sell moderately priced private-label and national brand clothing, shoes, accessories, cosmetics, and home furnishings. Most of these stores are in strip centers. Kohl's also operates a large digital sales business. Women's apparel is Kohl's largest category, having generated 27% of its 2021 sales. The retailer, headquartered in Menomonee Falls, Wisconsin, opened its first department store in 1962.
Read more on KSS →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
